Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75092 | 0.98 | CYP1A2 (0.50) | CYP1A2KDM4EPOLBNFE2L2ALDH1A1 | |
| SCHEMBL12461290 | 0.95 | — | — | |
| SCHEMBL14479645 | 0.90 | — | — | |
| SCHEMBL23815628 | 0.88 | CYP1A2 (0.56) | CYP1A2KDM4EPOLBNAAASIGMAR1 | |
| SCHEMBL24489452 | 0.86 | CYP1A2 (0.54) | CYP1A2KDM4EPOLBNAAASIGMAR1 | |
| SCHEMBL23014863 | 0.84 | CYP1A2 (0.52) | CYP1A2KDM4EPOLBNAAASIGMAR1 | |
| SCHEMBL5215905 | 0.84 | CYP1A2 (0.58) | CYP1A2KDM4EPOLBNAAASIGMAR1 | |
| SCHEMBL8986251 | 0.84 | NFE2L2 (0.42) | CYP1A2KDM4ENFE2L2ALDH1A1SIGMAR1 | |
| SCHEMBL16404829 | 0.83 | CYP1A2 (0.50) | CYP1A2NFE2L2SIGMAR1SMN1; SMN2 | |
| SCHEMBL23014969 | 0.82 | CYP1A2 (0.56) | CYP1A2KDM4EPOLBNAAASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | claimed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | claimed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-3022208-B1 | METHOD AND APPARATUS FOR THE SYNTHESIS OF DIHYDROARTEMISININ AND ARTEMISININ DERIVATIVES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-20150045357-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-02-12 | — | — | US | disclosed |
| US-8653262-B2 | CCR2 receptor antagonists and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| WO-2010098119-A1 | COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE COMPLEX COMPOUND | 三井化学株式会社 (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204209-A1 | CCR2 Receptor Antagonists and Uses Thereof | CCR2, CCRL2, CCR1 | CYP1A2 755/4885KDM4E 4483/4885POLB 4261/4885 |
| US-20150045357-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, BCL3 | CYP1A2 3904/4885KDM4E 1153/4885POLB 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.